According to a news from CNN a short time ago the FDA shut down 1,677 online pharmacies. It was reported that 58 people were arrested and that 41 million dollars worth of illegal, counterfeit drugs were seized from 100 different countries. According to The National Association of Boards of Pharmacy there are over 10,000 online [...]
The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not exist 4 years ago. With the addition of all these new options, so comes the addition of significant economic costs, [...]
The great news for for our brothers in Europe is that Xtandi (Enzalutamide) has been approved for use in the European Union (EU) for the treatment of men with metastatic castration-resistant prostate cancer whose disease has progressed on or after chemotherapy (docetaxel). Following the regulatory review process by the European Medicines Agency (EMA) and a [...]
Infections are among the scariest possibility whenever we go into the hospital, especially for any type of surgery. The good news is that since 2008 the national rates of certain hospital infections have declined significantly. We cancer survivors are more vulnerable to infection since many of our treatments including chemotherapy temporarily suppress our immune systems. [...]
Why does PSA continue to rise and prostate cancer disease continue to progress (new tumors develop and existing tumors continue to get bigger) when a man has an immune system treatment to go after their prostate cancer? This issue is probably the major marketing hurdle faced by Dendreon’s Provenge and based on the current statistics [...]
Many of us believe that prostate cancer is one specific disease, however this is not true. In fact we now know that there are at least twenty-three different types off prostate cancer. The most common types of prostate cancer, or ninety-five percent of them are referred to as adenocarcinomas. One of the least common types [...]
It was announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that PROVENGE® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or Sipuleucel-T) be granted marketing authorization in the European Union (EU), for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) [...]
There have been many potential targets identified for the treatment of advanced prostate cancer. Many of these targets are being actively explored with clinical trials designed to test some inhibitors of the targets. Antisense oligonucleotides (OGX-011) targets clusterin, a chaperone protein and OGX-427 which targets heat-shock protein 27 are among the inhibitors being evaluated. OGX-011 [...]
Osteoblasts and osteoclasts are the process that the body uses to breakdown old bone and then to rebuild it with new bone. c-Met is a tyrosine kinase expressed by osteoblasts and osteoclasts, and overexpressed by prostate cancer cells. This over expression leads to the eventual development of bone metastases. The experimental treatment known as Cabozantinib [...]
Are you the kind of guy that uses his laptop computer in your lap? Many of us do this when we are in our car or even seated on our couch while we watch TV. If we don’t most of our children and granchildren do. According to research presented at the American Society for Reproductive [...]
